Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 6/20 | 0.44 |
| ▸ | KIF11 | P52732 | 5/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | CBFB | Q13951 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL142611 | 0.85 | PKM (0.41) | NPBWR1KIF11METAP2DGAT1KCNH2 | |
| SCHEMBL11822368 | 0.83 | SCN10A (0.47) | KIF11METAP2KCNH2DYRK1ASCN10A | |
| SCHEMBL207131 | 0.75 | ALPL (0.41) | METAP2CBFBBACE1KDM4E | |
| SCHEMBL27847161 | 0.73 | PDPK1 (0.44) | KIF11DGAT1KCNH2 | |
| SCHEMBL207168 | 0.71 | ALDH1A1 (0.44) | METAP2DYRK1ACBFBBACE1KDM4E | |
| SCHEMBL207428 | 0.71 | ALDH1A1 (0.41) | METAP2DYRK1ABACE1KDM4E | |
| SCHEMBL15157341 | 0.70 | KIF11 (0.40) | KIF11METAP2KCNH2SCN10A | |
| SCHEMBL28069113 | 0.70 | TGFBR1 (0.43) | — | |
| SCHEMBL27672328 | 0.69 | CACNA1H (0.35) | KIF11METAP2 | |
| SCHEMBL27947326 | 0.69 | MAP4K4 (0.39) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101128452-B | Novel benzimidazole derivatives and pharmaceutical compositions containing the same | DAE WOONG PHARMA | 2012-11-21 | — | — | CN | claimed |
| WO-2011014520-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-02-03 | — | — | WO | claimed |
| WO-2009032840-A1 | FLUORINE- SUBSTITUTED 2 ', 6 ' -DIMETHYL-L-TYROSINE-1, 2,3, 4-TETRAHYDR0IS0QUIN0LINE-3-CARB0XYLIC ACID PEPTIDES (DMT-TIC) FOR USE AS MYU- AND DELTA-OPIOID RECEPTOR PROBES IN | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-03-12 | — | — | WO | claimed |
| CN-101128452-A | Novel benzimidazole derivatives and pharmaceutical compositions containing the same | DAE WOONG PHARMA (KR) | 2008-02-20 | — | — | CN | claimed |
| CN-1871232-A | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2006-11-29 | — | — | CN | claimed |
| WO-2011014520-A2 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-02-03 | — | — | WO | disclosed |
| CN-101842365-A | The phenyl isoquinolin quinoline and the phenylquinazoline derivates that are used for the treatment of osteopathia | NOVARTIS AG | 2010-09-22 | — | — | CN | disclosed |
| EP-2197872-A1 | PHENYLISOQUINOLINE AND PHENYLQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | Novartis Ag (CH) | 2010-06-23 | — | — | EP | disclosed |
| US-20090074791-A1 | Phenylisoquinoline and Phenylquinazoline Derivatives | BEERLI RENE | 2009-03-19 | — | — | US | disclosed |
| WO-2009027475-A1 | PHENYLISOQUINOLINE AND PHENYLQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF BONE DISEASES | NOVARTIS AG (CH) | 2009-03-05 | — | — | WO | disclosed |
| CN-101128452-A | Novel benzimidazole derivatives and pharmaceutical compositions containing the same | DAE WOONG PHARMA (KR) | 2008-02-20 | — | — | CN | disclosed |
| CN-1871232-A | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2006-11-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074791-A1 | Phenylisoquinoline and Phenylquinazoline Derivatives | CAMK1D, CAMK1, PHPT1 | NPBWR1 2442/4885KIF11 4543/4885METAP2 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.